Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04209725
Title A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SCRI Development Innovations, LLC

acute myeloid leukemia


CPX-351 + Quizartinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST